Plasmid-based CRISPR-Cas9 system efficacy for introducing targeted mutations in CD81 gene of MDA-MB-231 cell line.
Kasra Arbabi ZaboliHossein RahimiJose ThekkiniathAmir Hossein TaromchiSaeed KaboliPublished in: Folia histochemica et cytobiologica (2022)
Taken together, our data show that the CRISPR-Cas9 system can change the genomic sequence in the target area of MDA-MB-231 cells. Along with previous studies, we propose forethought when using T7E1-based quantitative indel estimates, as comparing activities of multiple gRNAs with the T7E1 assay may lead to inaccurate conclusions. Instead, estimating non-homologous end-joining events (NHEJ) by Sanger sequencing and subsequent TIDE analysis is recommended.
Keyphrases
- crispr cas
- cell cycle arrest
- genome editing
- dna repair
- breast cancer cells
- copy number
- induced apoptosis
- cell death
- pi k akt
- dna damage
- high throughput
- electronic health record
- big data
- single cell
- escherichia coli
- genome wide
- high resolution
- cancer therapy
- signaling pathway
- gene expression
- case control
- genome wide identification
- machine learning
- mass spectrometry
- dna methylation
- cell proliferation